These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26060823)

  • 21. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does bromocriptine improve glycemic control of obese type-2 diabetics?
    Aminorroaya A; Janghorbani M; Ramezani M; Haghighi S; Amini M
    Horm Res; 2004; 62(2):55-9. PubMed ID: 15205563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.
    Ezrokhi M; Zhang Y; Luo S; Cincotta AH
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma.
    Igata M; Yagi Y; Hanatani S; Sakaguchi M; Ishii N; Yoshinaga K; Kawashima J; Motoshima H; Araki E
    J Diabetes Investig; 2021 Apr; 12(4):668-671. PubMed ID: 32706496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of bromocriptine on cardiovascular complications associated with metabolic syndrome in fructose fed rats.
    Nade VS; Kawale LA; Todmal UB; Tajanpure AB
    Indian J Pharmacol; 2012; 44(6):688-93. PubMed ID: 23248395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Liang W; Gao L; Li N; Wang B; Wang L; Wang Y; Yang H; You L; Hou J; Chen S; Zhu H; Jiang Y; Pan H
    Horm Metab Res; 2015 Oct; 47(11):805-12. PubMed ID: 26332757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bromocriptine mesylate (Cycloset) for type 2 diabetes mellitus.
    Weiland CM; Hilaire ML
    Am Fam Physician; 2013 May; 87(10):718-20. PubMed ID: 23939451
    [No Abstract]   [Full Text] [Related]  

  • 29. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
    Defronzo RA
    Diabetes Care; 2011 Apr; 34(4):789-94. PubMed ID: 21447659
    [No Abstract]   [Full Text] [Related]  

  • 30. Bromocriptine: old drug, new formulation and new indication.
    Holt RI; Barnett AH; Bailey CJ
    Diabetes Obes Metab; 2010 Dec; 12(12):1048-57. PubMed ID: 20977575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations.
    Garber AJ; Blonde L; Bloomgarden ZT; Handelsman Y; Dagogo-Jack S
    Endocr Pract; 2013; 19(1):100-6. PubMed ID: 23337160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus.
    Kabir MT; Ferdous Mitu J; Akter R; Akhtar MF; Saleem A; Al-Harrasi A; Bhatia S; Rahman MS; Damiri F; Berrada M; Rahman MH
    Environ Sci Pollut Res Int; 2022 Jul; 29(31):46385-46404. PubMed ID: 35486279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
    Krysiak R; Gilowski W; Szkrobka W; Okopien B
    Cardiovasc Ther; 2015 Oct; 33(5):282-7. PubMed ID: 26146893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic memory: Evolving concepts.
    Misra A; Bloomgarden Z
    J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
    Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
    JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.